"The U.S. Food and Drug Administration today approved the MemoryShape Breast Implant to increase breast size (augmentation) for use in women at least 22 years old and to rebuild breast tissue (reconstruction) in women of any age. The MemoryShape B"...
The following adverse reactions are discussed in greater detail in other sections of the label:
- Nephrogenic systemic fibrosis [see WARNINGS AND PRECAUTIONS]
- Hypersensitivity reactions [see WARNINGS AND PRECAUTIONS]
Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.
Clinical Studies Experience (Adults)
In clinical studies 1160 patients were exposed to OMNISCAN. The most frequent adverse reactions were nausea, headache, and dizziness that occurred in 3% or less of the patients. The majority of these reactions were of mild to moderate intensity.
The following adverse reactions occurred in 1% or less of patients:
Application Site Disorders: Injection site reaction.
Autonomic Nervous System Disorders: Vasodilation.
Central and Peripheral Nervous System Disorders: Convulsions including grand mal, ataxia, abnormal coordination, paresthesia, tremor, aggravated multiple sclerosis (characterized by sensory and motor disturbances), aggravated migraine.
Liver and Biliary System Disorders: Abnormal hepatic function.
Special Senses, Other Disorders: Taste loss, taste perversion.
Urinary System Disorders: Acute reversible renal failure.
Vision Disorders: Abnormal vision.
Clinical Studies Experience (Pediatrics)
In the 97 pediatric patients in CNS studies with OMNISCAN [see Clinical Studies] and the 144 pediatric patients in published literature, the adverse reactions were similar to those reported in adults.
Because postmarketing reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.
The following adverse reactions have been identified during the postmarketing use of OMNISCAN:
Nervous System Disorders: Inadvertent intrathecal use causes seizures, coma, paresthesia, paresis.
General Disorders: Nephrogenic Systemic Fibrosis (NSF) [see WARNINGS AND PRECAUTIONS].
Read the Omniscan (gadodiamide) Side Effects Center for a complete guide to possible side effects
Specific drug interaction studies have not been conducted.
Last reviewed on RxList: 9/9/2013
This monograph has been modified to include the generic and brand name in many instances.
Additional Omniscan Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.